Navigation Links
Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
Date:4/10/2013

SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice. Using its proprietary high-throughput Cellular Redistribution Assay (CRA), Omeros believes that it alone has identified compounds that functionally interact with GPR17 and has patents pending that are broadly directed to any such compounds active at the receptor.

Having discovered compounds that functionally interact with GPR17, Omeros previously showed that GPR17 antagonists promote generation of mature oligodendrocytes, the cells that produce myelin. Myelin is a key component of the proper functioning of the central nervous system, and myelin deficiency is a hallmark of a large number of neurodegenerative autoimmune diseases, including MS. In this EAE model, animals treated with GPR17-targeting compounds, compared to untreated animals, significantly improved mean clinical scores, which quantify disease progression by measuring motor dysfunction and are used as a surrogate indicator of demyelination.

"Our GPCR platform – built around our proprietary CRA – continues to unlock wholly new drug targets, and we expect that our sole knowledge of the identities of their interacting compounds together with our patent positions will give Omeros exclusive control of those receptors," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "GPR17 is one of those
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
2. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
3. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
4. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
5. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
6. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
7. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
8. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
9. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
10. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
11. Omeros is Not Aware of Any Justification for Share Price Movement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
(Date:8/29/2014)... DIEGO , Aug. 29, 2014   ... emerging biopharmaceutical company, announced today that Santosh Vetticaden, ... be leaving the Company, for personal reasons, in ... Chief Medical Officer of Aires Pharmaceuticals, which Mast ... former responsibilities as the Company,s interim Chief Medical ...
Breaking Medicine Technology:Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Implementing a Strategic Thought Leader Management & Engagement System 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... Findings from an international,multicenter, randomized, double-blind, placebo-controlled Phase ... of moderate to severe,plaque psoriasis will be presented ... the World Congress of Dermatology, which takes place ... Aires, Argentina. The presentation, entitled CNTO 1275 ...
... Study Will Assess Drug,s Benefit, Alone and With Lipitor(R), ... Cholesterol and Triglycerides -, HAYWARD, Calif., Sept. 25 ... and development of novel,therapeutics for diabetes and related metabolic ... 2 trial of MBX-8025 in overweight or,obese patients with ...
Cached Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:9/2/2014)... At the 50th Annual Mr. Olympia ... an exhibitor at the Las Vegas Convention Center South ... 89109 Booth #374 Sept 19th and 20th 10am-5PM. ... through exercise, diet and supplementation. They pride themselves on ... tools for all Prosupps customers to reach their personal ...
(Date:9/2/2014)... Tuesday 2 September 2014: A simple awareness campaign ... (AF), according to research presented at ESC Congress today ... said: "Atrial fibrillation (AF) is the most common cardiac ... by three-fold and the risk of stroke risk by ... 1 of 4 cases. However, AF is often overlooked ...
(Date:9/2/2014)... 2 September 2014: The fact that mechanical heart valves ... by data from the ROPAC registry presented for the ... session by Professor Jolien W. Roos-Hesselink, co-chair with Professor ... found that 1.4% of pregnant women with a mechanical ... pregnancy. , The Registry Of Pregnancy And Cardiac disease ...
(Date:9/2/2014)... NOVAtime Technology, Inc. ( http://www.novatime.com ), a forward-thinking ... Avon Health Center, a long-time NOVAtime 3000 customer ... Time and Attendance / Workforce Management solution ... the NT7000 . , Avon Health Center in ... nursing facility that provides short-term rehabilitation, long-term care, ...
(Date:9/2/2014)... Productive Dentist Academy, a dental ... State, has been named to Inc. Magazine’s 5000 list ... the third year in a row it has obtained ... astonishing 63 percent growth rate and increased revenues from ... increased its number of employees from eight to 25. ...
Breaking Medicine News(10 mins):Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 2Health News:Avon Healthcare Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution with NT7000 Smart Clocks 3Health News:Dental Management Company Named to Fastest-Growing List Again 2Health News:Dental Management Company Named to Fastest-Growing List Again 3
... through which 3-month-old Jason Wolfe received a lung transplant, while ... // transplant in Ohio. The surgery was possible as a ... compatible to the two babies who were in need of ... lungs were transplanted to Jason, while the heart of Jason ...
... Centers for Disease Control and Prevention said that all samples ... to adamantanes, the class of drugs which is used for ... this class like amantadine and rimantadine are ineffectual for now ... ,The findings were reported in the Journal of the ...
... But now after bringing in changes in their sexual behavior, by ... and using condoms have greatly reduced the number of people suffering ... among women in the age group of 15-24 the prevalence of ... in the age group of 17-29. ,Hence the researcher, ...
... doesn’t seem to rest in the Asian peninsula. A new case ... died at Hasan Sadikin Hospital in the Indonesian town of Bandung.// ... WHO -accredited lab in Hong Kong it will become the 15th ... was a resident of Padalarang in Bandung regency, some150 km south ...
... suspected cases of bird flu have been reported in Iraq’s northern ... result of the disease. The // region’s diagnosis center has admitted ... virus. The Rania region of the north bordering Turkey is reported ... have spread from neighboring Turkey, which has seen four deaths and ...
... Severe earthquakes can result due to tectonic plates colliding with ... severe damage can be caused // by the subduction zone. ... The earth's surface is laced with about 51,000 kilometers of ... zones averages a slip of about two inches per year. ...
Cached Medicine News:Health News:Resistant Influenza strains creates panic in US 2
The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Apron,special Proceddure...
Crisscross shoulder design facilitates better posture and distributes weight to back and hips for greater comfort. Shoulder pads soften shoulder contact with apron for additional comfort....
Medicine Products: